Carboplatin and paclitaxel dose dense as neoadjuvant chemotherapy follow by interval cytoreduction in advanced ovarian cancer.

e16553 Background: Neoadjuvant chemotherapy with Carboplatin and Paclitaxel every 3 weeks show higher rates in optimal debulking surgery compared with those primarily operated. We explored Carboplatin and Paclitaxel dose-dense as neoadjuvant treatment for advanced ovarian carcinoma. Methods: Patients with primarily unresectable epithelial ovarian cancer was treated with carboplatin (AUC 6) day 1 plus paclitaxel 80 mg/m2 every week, Days 1-8-15 every 21 days for three cycles follow by interval cytoreduction and adjuvant chemotherapy for three more cycles. The main objective was rate of optimal cytoreduction and secondary objectives: pathologic response rate, time to progression, progression-free survival (PFS), overall survival (OS) and toxicity profile. Results: Between Jan-2011 and Dec-2013, 39 patients received neoadjuvant treatment, median age: 58 years (47-73), status performance, ECOG 1: 24 (61.5%). EC III-C/IV = 26/13. High grade serous adenocarcinoma 26 (66.7%), unspecified serous 10 (25.6%), Mucin...